Bliss GVS Pharma (BLISSGVS) | Stock Overview & Key Data
Bliss GVS Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹150.86
High: ₹153.95
on October 3, 2025
52 Week Range
Low: ₹106.04
High: ₹190.97
on October 25, 2024
on July 31, 2025
All-Time High: ₹221.00 on December 28, 2020
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR16.2B
EPS
10.06
P/E Ratio (TTM)
15.21
Forward P/E
N/A
P/B Ratio
1.53
PEG Ratio
0.14
Div. Yield
0.33%
ROE
7.72%
Beta
0.977
Debt to Equity
8.07
Financial Highlights
Profitability
Gross Margin
55.71%
Operating Margin
15.97%
Profit Margin
12.79%
Returns and Earnings
Return on Assets (TTM)
6.48%
Return on Equity (TTM)
7.72%
EBITDA
INR2.0B
Net Income (TTM)
INR1.1B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR79.11
Quarterly Revenue Growth (YoY)
13.00%
Quarterly Earnings Growth (YoY)
107.90%
Dividend Information
Last 12-Month Dividend
₹0.50
Current Dividend Yield
0.33%
3-Year Average Dividend Yield
0.44%
3-Year Average Annual Dividend
₹0.50
3-Year Total Dividends
₹1.50
Ex-Dividend Date
July 24, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Bliss GVS Pharma BLISSGVS | 16.20B Small-cap | 4.55% | -4.59% | -3.15% | 20.05% | -14.71% | 16.20% | 100.50% | -13.67% |
| Sun Pharmaceutical SUNPHARMA | 4.01T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Suven Life Sciences SUVEN | 47.99B Small-cap | -0.17% | -3.10% | -15.83% | 58.82% | 63.15% | 46.77% | 186.97% | 307.88% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Aarti Drugs AARTIDRUGS | 44.55B Small-cap | 4.61% | 0.24% | 1.59% | 41.06% | 7.93% | -4.79% | -0.89% | -50.06% |
Ownership & Short Interest
Insider Ownership
60.62%
Institutional Ownership
7.14%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
725K
Average 90-Day Volume
610K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BLISSGVS's 52-week high and low?
- In the last 52 weeks, Bliss GVS Pharma reached a high of ₹190.97 (on July 31, 2025) and a low of ₹106.04 (on October 25, 2024).
- What is the market cap and P/E ratio for BLISSGVS?
- Curious about Bliss GVS Pharma's size and valuation? Its market capitalization stands at 16.20B. When it comes to valuation, the P/E ratio (trailing twelve months) is 15.21, and the forward P/E (looking ahead) is N/A.
- Does BLISSGVS pay dividends? If so, what's the yield?
- Yes, Bliss GVS Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.33%, and the company has paid an average of ₹0.50 per share annually over the past 3 years.
- Who are Bliss GVS Pharma's main competitors or similar companies to consider before investing?
When looking at Bliss GVS Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA4.01T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Suven Life Sciences
SUVEN47.99B Healthcare Drug Manufacturers - Specialty & Generic 46.77% 186.97% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Aarti Drugs
AARTIDRUGS44.55B Healthcare Drug Manufacturers - Specialty & Generic -4.79% -0.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bliss GVS Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Bliss GVS Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.72%, the Debt to Equity ratio from the most recent quarter is 8.07, and its Gross Profit Margin stands at 55.71%.
- What is the recent revenue and earnings growth for BLISSGVS?
- Looking at Bliss GVS Pharma's growth, its revenue over the trailing twelve months (TTM) was INR8B. Compared to the same quarter last year (YoY), quarterly revenue grew by 13.00%, and quarterly earnings saw a YoY growth of 107.90%.
- How much of BLISSGVS stock is held by insiders and institutions?
- Wondering who owns Bliss GVS Pharma stock? Company insiders (like executives and directors) hold about 60.62% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 7.14%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.